Exploring the Validity of GOLD 2023 Guidelines: Should GOLD C and D Be Combined?

INTRODUCTION: The GOLD (Global Initiative for Chronic Obstructive Lung Disease) 2023 guidelines proposed important changes to the stratification of disease severity using the “ABCD” assessment tool. The highest risk groups “C” and “D” were combined into a single category “E” based on exacerbation history, no longer considering symptomology. PURPOSE: We quantify the differential disease progression of individuals initially stratified by the GOLD 2022 “ABCD” scheme to evaluate these proposed changes. PATIENTS AND METHODS: We utilise data collected from 1529 users of the myCOPD mobile app, a widely used and clinically validated app supporting people living with COPD in the UK. For patients in each GOLD group, we quantify symptoms using COPD Assessment Tests (CAT) and rate of exacerbation over a 12-month period post classification. RESULTS: CAT scores for users initially classified into GOLD C and GOLD D remain significantly different after 12 months (Kolmogorov–Smirnov statistic = 0.59, P = 8.2 × 10(−23)). Users initially classified into GOLD C demonstrate a significantly lower exacerbation rate over the 12 months post classification than those initially in GOLD D (Kolmogorov–Smirnov statistic = 0.26; P = 3.1 × 10(−2); all exacerbations). Further, those initially classified as GOLD B have higher CAT scores and exacerbation rates than GOLD C in the following 12 months. CONCLUSION: CAT scores remain important for stratifying disease progression both in-terms of symptomology and future exacerbation risk. Based on this evidence, the merger of GOLD C and GOLD D should be reconsidered.